On Demand Activities

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer

0.50 hr(s) | CME , MOC

Specialty: Oncology , Gynecology

Therapeutic Area(s): Oncology , Gynecology

Release Date: April 30, 2020

Expiration Date: April 29, 2021

Location: Internet Activity Enduring Material

In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer.

1 10 11 12
Copy link
Powered by Social Snap